Heron Therapeutics, Inc. — Q2 2016 Form 10-Q Summary
Business context and reporting period
Heron Therapeutics is a pre-commercial biotechnology company developing SUSTOL for chemotherapy-induced nausea and vomiting, HTX-019 for chemotherapy-induced nausea and vomiting, and HTX-011 for post-operative pain. The filing covers the quarter and six months ended June 30, 2016. The interim financial statements are unaudited.
Financial performance and liquidity
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | None reported | None reported |
| Net loss | $43.2 million, versus $23.1 million | $76.7 million, versus $43.7 million |
| Net loss per share | $1.17, versus $0.74 | $2.09, versus $1.45 |
| Operating expenses | $43.1 million, versus $23.0 million | $76.4 million, versus $43.4 million |
| Net cash used in operating activities | $27.1 million | $59.5 million, versus $35.5 million |
Operating expenses comprised research and development of $27.3 million for the quarter and $43.4 million year to date; general and administrative expense of $4.8 million and $10.1 million; and sales and marketing expense of $11.0 million and $22.9 million, respectively. The filing does not provide a meaningful gross or operating margin because the company had no reported product revenue.
- Cash and cash equivalents were $61.9 million at June 30, 2016, compared with $75.2 million at December 31, 2015.
- Short-term investments were $12.7 million, compared with $56.0 million at year-end 2015, resulting in total cash, cash equivalents and short-term investments of approximately $74.6 million versus $131.2 million.
- Total assets were $85.7 million and total stockholders’ equity was $57.8 million at June 30, 2016.
- Accumulated deficit was $489.5 million.
- Current liabilities were $27.9 million, including $2.6 million of convertible notes payable to related parties, net of discount.
- The company had $5.8 million of convertible-note principal outstanding, convertible into approximately 7.3 million common shares. The notes bear 6% interest, are secured by substantially all assets, mature in 2021, and may be subject to holder-requested prepayment.
- Stock-based compensation was $11.2 million for the first six months, compared with $5.7 million in the prior-year period.
Material changes versus the prior comparable period
- Net loss increased 87% for the quarter and 76% for the first six months, primarily reflecting higher clinical, manufacturing, pre-commercialization, personnel and stock-based compensation costs.
- Research and development expense increased 69% for the quarter and 41% year to date. HTX-011 clinical and manufacturing costs increased substantially, while SUSTOL costs declined following completion of its Phase 3 program in May 2015.
- Sales and marketing expense increased to $11.0 million for the quarter and $22.9 million year to date from $2.8 million and $5.0 million, respectively, as the company hired and trained a sales force and prepared for a potential SUSTOL launch.
- Operating cash use increased to $59.5 million year to date from $35.5 million. Investing cash flow was $41.2 million positive, primarily because of maturities of short-term investments; financing cash flow was $5.0 million positive, primarily from stock-option exercises.
- The company capitalized $3.3 million of SUSTOL pre-launch inventory during the first half of 2016. This inventory could require a material write-off if approval is delayed, denied, or requires different manufacturing specifications.
Guidance, outlook, commentary and risks
- SUSTOL’s NDA remained under FDA review. The FDA did not act by the January 17, 2016 PDUFA goal date; in April 2016, the company stated that no substantive deficiencies had been identified and that labeling discussions had begun. SUSTOL was not approved as of the filing.
- Management intended to file an NDA for HTX-019 in the fourth quarter of 2016 under the 505(b)(2) pathway.
- HTX-011 remained in Phase 2 development. The filing describes positive preliminary results from two studies, but those results were reported in August 2016, after the quarter-end reporting date, and remain subject to confirmation in later trials.
- On August 2, 2016, the company entered into a related-party loan agreement with Tang Capital Partners for up to $100 million. The first $50 million closed on August 5, 2016; the additional $50 million is contingent on achievement of a corporate milestone. The loan has a two-year term, bears 8% interest, has a second-priority lien on substantially all assets, and has no warrants or equity conversion feature.
- Management expects continuing substantial losses and negative operating cash flow until meaningful product revenue is generated. Additional financing may be required, and funding may be unavailable or available only on unfavorable or dilutive terms.
- Key risks include further SUSTOL regulatory or labeling delays, manufacturing and supply-chain deficiencies, failure of later-stage clinical trials, dependence on third-party manufacturers and contract research organizations, competitive products and generics, reimbursement and pricing pressure, intellectual-property challenges, product liability, and dilution or restrictions associated with secured debt.
- The company reported no legal proceedings and no off-balance-sheet arrangements. Management concluded that disclosure controls and procedures were effective as of June 30, 2016.
Most important facts for investors to verify
- Current FDA status, approval timing, final labeling, and manufacturing conditions for SUSTOL.
- Whether HTX-019’s planned fourth-quarter 2016 NDA filing occurred and the regulatory outcome.
- Whether HTX-011 Phase 2 results are replicated in adequately powered Phase 3 trials.
- Cash runway under current operating cash burn and the conditions, covenants, and collateral provisions of the related-party loan.
- Potential dilution from approximately 7.3 million shares underlying the convertible notes, plus outstanding stock options.
- Recoverability of the $3.3 million SUSTOL pre-launch inventory balance if approval or launch is delayed.
- Ability of third-party manufacturers to resolve prior FDA-related deficiencies and scale production for commercial launch.